Substance P and neurokinins as stimulants of the human isolated urinary bladder

Neurokinins are active stimulants of the human isolated urinary bladder. In a preliminary study, performed on bladders taken from four donors, we attempted the characterization of neurokinin receptors. It was shown that neurokinin A is more active than neurokinin B and substance P. Neurokinin receptors selective agonists were also tested and it was found that the most active compound was the NK-A selective agonist, [Nle10]NKA 4-10: A substance P antagonist was able to reduce the effect of neurokinin A but its affinity was rather low. This suggests that the receptor mediating the contraction of the human urinary bladder to neurokinins is of the NK-A (NK2) type. The action of neurokinins on the human urinary bladder appears to be a direct one and mediated by specific receptors different from those of other agents. On the contrary, kinins were found to be active through a new mechanism which was not influenced by either anti-B1 or anti-B2 receptor antagonists.     

C-FOS expression in the rat brain in response to substance P and neurokinin B

Substance P, the principal neurokinin peptide in the mammalian brain and the natural ligand for the NK(1) tachykinin receptor, plays an integrative role in the regulation of cardiovascular, neuroendocrine and behavioural responses to stress. In rats, stimulation of periventricular NK(1) receptors in the forebrain induces a distinct pattern of cardiovascular responses which is accompanied by intense grooming behaviour. Ligands for NK(3) receptors induce a different pattern of cardiovascular and behavioural responses which comprises an increased release of vasopressin from the posterior pituitary and wet-dog shakes behaviour. To define the brain areas in the rat which respond to stimulation of forebrain NK(1) and NK(3) receptors and participate in the generation of these responses, the induction of c-Fos immunoreactivity was examined in brains following intracerebroventricular injections of substance P and neurokinin B in conscious rats. Stimulation of central NK(1) receptors by substance P (25, 100 and 500 pmol) injected into the lateral ventricle elicited grooming behaviour (face washing and hind limb grooming) and resulted in a marked c-Fos expression in the paraventricular, dorsomedial and parabrachial nuclei and in the medial thalamus. At 25 pmol, substance P did not significantly increase c-Fos expression, at 100 pmol, maximal c-Fos activation was induced in all four brain regions which responded to the peptide. Intracerebroventricular pretreatment of rats with the selective and high-affinity, non-peptide NK(1) receptor antagonist, RP 67580 (500 pmol), but not with its inactive enantiomer, RP 68651, completely abolished the behavioural response to substance P and reduced the substance P-induced c-Fos expression in all brain areas to nearly control levels. Intracerebroventricular injection of the natural ligand for NK(3) receptors, neurokinin B (500 pmol), elicited wet-dog shakes behaviour and activated c-Fos expression in localized regions of the forebrain including the organum vasculosum laminae terminalis, subfornical organ, median preoptic nucleus, paraventricular, supraoptic and anterior hypothalamic nuclei, medial thalamus and in the ventral tegmental area. These results demonstrate that the neurokinins, substance P and neurokinin B, induce specific and different patterns of c-Fos expression in distinct regions of the rat brain. Brain areas which selectively responded to substance P have been traditionally linked to the central regulation of cardiovascular and neuroendocrine reactions to stress or involved in the processing of nociceptive responses. On the other side, brain areas activated by neurokinin B are known to be involved in the central regulation of blood pressure, water and salt homeostasis or control of behaviour.     

Activation of substance P receptors leads to membrane potential responses in cultured astrocytes

Cultured astrocytes from rat cortex and spinal cord responded with different types of membrane potential changes upon brief (10 seconds) applications of the natural neurokinin agonists substance P and neurokinin A. The most prominent type of response was a long-lasting membrane depolarization. In some cells, an initial rapid depolarization followed by a partial repolarization preceded the slow depolarizing event. Few astrocytes responded with a hyperpolarization of the membrane. Selective agonists at the NK-1 receptive site, substance P-methyl ester (SP-OME) and septide, mimicked the response to the natural neurokinins as did DiMe-C7, a selective NK-3 receptor agonist. A putative neurokinin antagonist, (D-Arg1,D-Pro2,D-Trp7,9,Leu11)SP (DADPDT) partially blocked membrane potential responses induced by substance P, SP-OME, septide, DiMe-C7, and NKA. The authors conclude that astrocytes express NK-1 and NK-3 receptors, which upon activation affect the electrical properties of these cells.     

Possible Role(s) of Neurokinins in CNS Development and Neurodegenerative or Other Disorders

RAFFA, R.B., Possible role(s) of neurokinins in CNS development and neurodegenerative or other disorders. NEUROSCI BIOBEHAV REV 22(6) 789–813, 1998.—The present review is an attempt to summarize the diverse literature that suggests a role for neurokinins in a variety of CNS developmental or disease processes. The role of neurokinins in (anti)nociception is well known and is the subject of other comprehensive reviews. The focus of this review is on associations that implicate substance P or other neurokinins in certain aspects of CNS development and in various neuropathologic disorders that have neurodegenerative, psychiatric or other clinical manifestations. Also included are associations related to the central control of some “peripheral” functions. The amount and degree of evidence for neurokinin involvement in each situation vary from strong to speculative—critical analyses and commentaries on individual methodologies and studies are available from other sources. When viewed in this broad context, the information suggests intrinsic neuroprotective or neurodegenerative properties of neurokinins. It is proposed that these properties delineate a specialized area within the broader field of neurokinin research.     

Effects of neurokinins on human colonic motility

Abstract Neurokinins have been implicated as excitatory neuromessengers involved in the mediation of different reflexes in the mammalian gastrointestinal tract. However, marked interspecies variations in reported receptor distribution and in regional peptide content do not allow the extrapolation of results obtained in animals to the human gastrointestinal tract. To characterize the myogenic and neurogenic mechanical response of human colonic muscle to neurokinins, we studied the inotropic response of muscle strips from the proximal and distal human colon, and the rectum to the NK-1 receptor agonists substance P (SP) and substance P methylester (SPME), to the NK-2 receptor agonists neurokinin A (NKA) and neurokinin A 4–10 (NKA4–10) and to the NK-3 receptor agonist neurokinin B (NKB). Even though all neurokinins caused a dose-dependent inotropic response, NKA was 15–20 times more potent than SP or SPME in all areas of the colon. The efficacy and potency of NKA was highest in distal circular colon. The response to exogenous SP and NKA was partially mediated by actions of these peptides on myenteric nerves, as indicated by the sensitivity of the mechanical response to atropine, tetrodotoxin and hexamethonium. Densensitization to NKA, but not to SP significantly increased the atropine-resistant part of the off response to electrical field simulation. These results suggest the following: (a) NKA is a potent agonist in human colon with a proximal to distal gradient in potency and in efficacy; (b) the response to NK-I, NK-2 and NK-3 agonists involves cholinergic and nicotinic mechanisms; (c) the increase in the atropine resistant off-response after desensitization with NKA is consistent with the existence of inhibitory NK-2 receptors on non-cholinergic myenteric neurons.     

Functional development of neurokinin peptides substance P and neurokinin A in nociception

It is unclear how neonates respond to noxious stimuli. This study examined the role of neurokinin peptides in 3- and 21-day-old rat pups using the preprotachykinin-A (PPTA) knockout mouse, lacking neurokinin A and substance P. We assessed pain behaviors of these mice before the neurokinin system is putatively active, 3 days after birth, and after this system is active, 21 days after birth. The lack of these peptides failed to alter behavioral responses to nociceptive stimulation in the 3-day-old mice. The 21-day-old mice lacking these peptides were less responsive to 5 microl 2% formalin and to high intensity thermal and mechanical stimuli. Thus, the neurokinins appear not to be an important mechanism in the processing of nociceptive information in the infant.     

Immunocytochemical localization of neurokinin B in the rat spinal dorsal horn and its association with substance P and GABA: an electron microscopic study

Substance P and neurokinin B are tachykinins that derive from different precursors. Both tachykinins are known to be involved in the processing of pain-related information. Initial studies suggested an antinociceptive effect for neurokinin B, but more recent data indicate that neurokinin B facilitates nociception. Unfortunately, morphologic correlates are lacking, as little is known about the distribution of neurokinin B, especially at the ultrastructural level. Because of its potentially important role in the processing of pain-related information, we decided to investigate the synaptic interactions of neurokinin B-immunoreactive profiles in laminae I-III of the rat cervical spinal dorsal horn and their relation to substance P-immunoreactive structures. An antibody raised against a portion of the neurokinin B precursor peptide was used for the detection of neurokinin B. Neurokinin B-like immunoreactivity occurred in all superficial laminae, with the highest density in inner lamina II and the lowest in lamina III. Neurokinin B-like immunoreactive axonal boutons were mainly dome-shaped and established symmetric synaptic contacts with dendrites or cell bodies. Neurokinin B-like immunoreactivity was also detected in dendritic profiles in all superficial laminae. Some of these dendritic profiles were part of synaptic glomeruli in inner lamina II and lamina III. Double-labeling for neurokinin B and substance P showed a lack of appositions and synapses between neurokinin B and substance P-positive profiles. Furthermore, very few profiles double-labeled for the two peptides were observed. Double-labeling for gamma-aminobutyric acid (GABA) and neurokinin B showed a complete absence of neurokinin B/GABA co-localization. Furthermore, neurokinin B-positive profiles were never presynaptic to GABA-immunoreactive profiles, but frequently neurokinin B-positive dendrites were postsynaptic to GABA-immunoreactive boutons. These results suggest that neurokinin B participates in circuits separate from those involving substance P, as virtually no anatomic correlation was found between the two neuropeptides.     

Comparison of the effects of substance P, neurokinin A, physalaemin and eledoisin in facilitating a nociceptive reflex in the rat

The postulated existence of different types of tachykinin receptor in the spinal cord provided the basis for the present study; substance P, neurokinin A, eledoisin and physalaemin were administered intrathecally in the awake, restrained rat to compare their effects on reaction time in the tail-flick test. Each peptide was delivered via a chronically implanted subdural catheter to the lower lumbar vertebral level of the spinal cord. Intrathecal administration of 10 micrograms of substance P (6.5 nmol), eledoisin (8.0 nmol) or physalaemin (7.9 nmol) decreased the reaction time, respectively, to 22.5, 24.3 and 20.8% of the mean preadministration control values at 1 min after injection; similar administration of 6.5 nmol of neurokinin A produced a smaller decrease in reaction time, to only 49.5% of preadministration values. These effects were transient, the reaction times returning to preadministration values within 5 min. Each peptide also produced an initial vocalization followed by increased restlessness. Analysis of the dose-response curves indicated that the rank order of potency of the fitted curves for these peptides was physalaemin greater than or equal to substance P greater than or equal to eledoisin greater than neurokinin A. The results suggest that the receptor involved in facilitation of the tail-flick reflex resembles a substance P receptor rather than a receptor for one of the other endogenous neurokinins and that this receptor may bear some resemblance to the SP-P type postulated to exist in peripheral tissues.     

Inhibition of calcium channels by neurokinin receptor and signal transduction in hamster submandibular ganglion cells.

Both substance P (SP) and neurokinin A (NKA) are known as neurotransmitters of the submandibular ganglion (SMG) neurons. SP released from collaterals of the sensory nerves also regulates the excitability of SMG neurons. It has recently been shown that neurokinins (NK) inhibit calcium channels in various neurons. In this study, the effects of NK on voltage-dependent calcium channel current (I(Ca)) in SMG cells were investigated using the whole-cell patch-clamp recording method. NK-1 receptor agonist and SP caused inhibition of I(Ca) in SMG cells in a dose-dependent manner. NK-1 receptor agonist inhibited L-, N- and P/Q-type I(Ca) components. GDP-beta-S included in the pipette solution reduced the NK-1 receptor agonist-induced inhibition of I(Ca). In addition, NK-1 receptor agonist-induced inhibition of I(Ca) was reduced by stimulation of protein kinase C (PKC) but not cyclic AMP-dependent protein kinase (PKA). The results provided evidence for a signal transduction pathway in which calcium channel inhibition by NK receptors required activation of G-protein and PKC-affected step phosphorylation in SMG neurons.     

Myoelectric pattern and effects on small bowel transit induced by the tachykinins neurokinin A, neurokinin B, substance P and neuropeptide K in the rat

Effects of neurokinin A, neurokinin B, substance P and neuropeptide K on myoelectric activity in the small intestine were related to intestinal transit of a radioactive marker in fasted conscious rats. Myoelectric activity was recorded using bipolar electrodes implanted at 5, 20 and 35 cm distal to pylorus. Intravenous infusions of neurokinin A, neurokinin B and neuropeptide K at doses of 50–200 pmol kg^?1 min^?1 and substance P at doses of 100–300pmol kg^?1 min^?1, disrupted migrating myoelectric complexes and induced irregular spiking. These effects were not prevented by atropine, hexamethonium or mepyramine. However, the effect of neurokinin A was attenuated by spantide. The irregular spiking induced by the tachykinins was associated with increased transit of the marker in animals receiving neurokinin A and neurokinin B, but not substance P and neuropeptide K. We conclude that the tachykinins activate the smooth muscle layers of the small intestine in the rat by mechanisms involving neurokinin receptors, but not muscarinic, nicotinic or H₁-receptors. Our results suggest a role for tachykinins in regulation of motility by induction of irregular spiking, which may stimulate transit through the small intestine.     

Ontogeny of the distribution of tachykinins in rat cerebral cortex: immunocytochemistry and in situ hybridization histochemistry

Tachykinins in the mammalian brain are derived from two genes: preprotachykinin A, encoding substance P and neurokinin A, and preprotachykinin B, encoding neurokinin B. Using immunocytochemistry and in situ hybridization histochemistry, we have investigated the ontogeny and distribution of substance P and neurokinin B in various cortical areas of rat cerebrum at different prenatal and postnatal ages. Preprotachykinin A mRNA-positive and -immunoreactive cells were first detected at birth and were abundant in layer VIb and the adjacent while matter in the cingulate and frontal cortices. By postnatal day 5, the numbers of substance P-expressing cells were diminished dramatically in those layers. However, their number gradually increased and spread out laterally to cover parietal and temporal cortices from P5 to P15 in layer V. At these stages, cells were also observed in layer II, although fewer in number. The number of substance P mRNA-positive neurons and substance P-immunoreactive cells decreased gradually from P10 and P15 onward, respectively. On the other hand, expression of neurokinin B, as detected by in situ hybridization histochemistry or immunocytochemistry, was not evident until P10. Neurons expressing this tachykinin were concentrated in layer II, and to a lesser extent in layers V and VI. This pattern of distribution was retained through P45. The present data show a marked difference between these two tachykinins in onset and trends of development, suggesting functional independence of these two tachykinins in the cerebral cortex.     

Distinct regional distributions of NK1 and NK3 neurokinin receptor immunoreactivity in rat brainstem gustatory centers

Tachykinins and their receptors are present in gustatory centers, but little is known about tachykinin function in gustation. In this study, immunohistochemical localization of substance P and two centrally prevalent neurokinin receptors, NK1 and NK3, was carried out in the rostral nucleus of the solitary tract and the caudal parabrachial nucleus to evaluate regional receptor/ligand correspondences. All three proteins showed regional variations in labeling density that correlated with distinct sites in gustatory centers. In the rostral nucleus of the solitary tract, the relative densities of substance P and NK1 receptors varied in parallel across subnuclei, with both being moderate to dense in the dorsocentral, chemoresponsive zone. NK3 receptors had a distinct distribution in the caudal half of this zone, suggesting a unique role in processing taste input from the posterior tongue. In the caudal parabrachial nucleus, substance P and NK1 receptor immunoreactivities were dense in the pontine taste area, while NK3 receptor labeling was sparse. The external medial subnucleus had substantial NK3 receptor and substance P labeling, but little NK1 receptor immunoreactivity. These findings suggest that distinct tachykinin ligand/neurokinin receptor combinations may be important in local processing of information within brainstem gustatory centers.     

Tachykinin activation of human monocytes from patients with rheumatoid arthritis: in vitro and ex-vivo effects of cyclosporin A

Three types of tachykinin receptors, namely NK1, NK2 and NK3, are known to preferentially interact with substance P (SP), neurokinin A (NKA) and neurokinin B (NKB), respectively. We previously demonstrated that NK1 and NK2 receptors are present on human monocytes, SP and NKA inducing superoxide anion production and tumor necrosis factor-alpha (TNF-alpha) mRNA expression. NK2 receptor stimulation also triggered an enhanced respiratory burst in monocytes isolated from rheumatoid arthritis (RA) patients. This study was aimed to evaluate the in vitro and ex-vivo effects of cyclosporin A (CsA) on tachykinins-evoked TNF-alpha release from monocytes of healthy donors and RA patients. CsA (100 ng/ml) potently inhibited phorbol ester- and tachykinin-evoked TNF-alpha secretion. In RA patients treated with CsA (Sandimmun Neoral 2.5 mg/kg/day, a significant time-dependent reduction in TNF-alpha secretion from monocytes was measured. This may contribute to the CsA therapeutic activity in RA.     

Localization of substance P binding sites in submucous plexus of guinea pig ileum, using whole-mount autoradiography

Whole mounts of guinea pig ileum submucosa were incubated with radiolabeled tachykinins, and binding sites were visualized using autoradiography. Very dense specific binding for [125I]-Bolton-Hunter substance P (BHSP) was observed over ganglia of the submucous plexus, with weaker binding over internodal strands. Dense specific binding was also seen over occasional strands of circular muscle, with weak binding over clumps of mucosa. Although very weak binding was seen over some large blood vessels, no binding was associated with smaller blood vessels. Localization of binding was absent in whole-mounts coincubated with 1 microM substance P, used to define nonspecific binding. Localization of BHSP-specific binding was also abolished in whole-mounts coincubated with 1 nM substance P, but not with 1 nM neurokinin B, suggesting that binding was probably to an NK-1 tachykinin receptor. In whole-mounts incubated in [125I]-iodohistidyl neurokinin A (INKA) or [125I]-Bolton-Hunter neurokinin B (BHNKB), no specific binding over ganglia was observed. These binding sites for BHSP are probably identical with the neuronal substance P receptors mediating mucosal ion transport.     

Substance P release in the dorsal horn assessed by receptor internalization: NMDA receptors counteract a tonic inhibition by GABA(B) receptors

Inhibitory amino acids have antinociceptive actions in the spinal cord that may involve inhibition of neurotransmitter release from primary afferents. Rat spinal cord slices with dorsal roots were used to study the effect of GABA and glycine on substance P release, assessed by the internalization of neurokinin 1 receptors. After electrical stimulation of the dorsal root at 100 Hz, about half of neurokinin 1 receptor-immunoreactive neurons in laminae I-IIo showed internalization. This internalization was inhibited by GABA (100 microM) and the GABA(B) agonist R-baclofen (10 microM), but not by the GABA(A) agonist muscimol (20 microM) or glycine (100 microM). The GABA(B) antagonist 2-hydroxysaclofen (100 microM) reversed the inhibitory effect of GABA, but not the GABA(A) antagonist bicuculline (100 microM). These findings demonstrate that GABA(B) receptors, but not GABA(A) or glycine receptors, inhibit substance P release induced by dorsal root stimulation. In contrast, R-baclofen did not inhibit the internalization produced by NMDA (100 microM), indicating that the stimulatory effect of NMDA receptors on substance P release is able to surmount the inhibitory effect of GABA(B) receptors. In the presence of the GABA(B) antagonist 2-hydroxysaclofen (100 microM), but not in its absence, stimulation of the dorsal root at 1 or 10 Hz was able to elicit internalization, which was not inhibited by the NMDA receptor antagonist AP-5 (50 microM) or the channel blocker MK-801 (10 microM). Therefore, inhibition of substance P release by GABA(B) receptors is tonic, and in its absence SP release no longer requires NMDA receptor activation.     

Selective agonists for substance P and neurokinin receptors

A series of neurokinin analogues and fragments have been prepared in an attempt to identify selective agonists for NK-P, NK-A and NK-B receptors. The compounds have been tested on the dog carotid artery (NK-P receptor system), the rabbit pulmonary artery (NK-A) and the rat portal vein (NK-B). C-terminal substituted analogues of the three neurokinins have provided indication that NK-P receptor selectivity is improved by the oxidation of methionine to Met(O2), while selectivity for NK-A is favoured by replacing Met with NIe. Selectivity for NK-P receptors is further improved by the replacement of Gly9 with Sar. Selectivity and affinity for NK-B receptors is markedly increased when Val7 is replaced with MePhe in both the fragment NKB (4-10) and NKB. The results of the present study indicate that a) [Sar9,Met(O2)11]SP is a potent and selective agonist for the NK-P receptors of the dog carotid artery; b) [MePhe7]NKB is a very potent and selective stimulant of receptors for neurokinin B and c) [Nle10]NKA (4-10) is a promising compound, showing some selectivity for NK-A receptor; further modifications are however needed to improve its affinity.     

The common carboxyl-terminal region of novel tachykinin peptides contributes to induce desensitization in scratching behavior of rats

Some novel tachykinin peptides exhibiting homology with known members of the tachykinin family have been recently reported; however, little is known about the function of these peptides. Repeated intrathecal administration of substance P (SP) causes desensitization by binding SP to neurokinin 1 (NK1) receptor. Thus, to clarify the characteristics of the receptors involved in these novel peptides, we investigated whether desensitization is induced by intrathecal administration of these peptides in rats since desensitization is induced by binding these peptides to the receptor. Intrathecal administration of 10(-3) M hemokinin-1 (HK-1) and 10(-3) M decapeptide common in the carboxyl-terminal region of endokinin A and endokinin B (EKA/B) as well as SP evoked scratching behavior. When each peptide was administered twice with an interval of 15 min, remarkable desensitization of scratching behavior was produced. Furthermore, the first administration of EKA/B or SP produced clear cross-desensitization to SP, EKA/B and HK-1, whereas the first administration of HK-1 demonstrated weak cross-desensitization to EKA/B and SP. These results suggest that EKA/B and SP may bind to both the NK1 receptor and HK-1-preferred receptor, and HK-1 may preferentially bind to its preferred receptor.     

Tachykinin receptors on human monocytes: their involvement in rheumatoid arthritis

Three types of tachykinin receptors, namely NK1, NK2 and NK3, are known to preferentially interact with substance P (SP), neurokinin A (NKA) and neurokinin B (NKB), respectively. Experimental evidence indicates that SP and NKA modulate the activity of inflammatory and immune cells, including mononuclear ones. This study evaluated the effects of mammalian tachykinins and selective tachykinin agonists and antagonists on human monocytes isolated from healthy donors: SP, NKA and NKB all evoked a dose-dependent superoxide anion (O2-) production and the NK2 selective agonist [beta-Ala8]-NKA(4-10) induced a full response. The NK3 selective agonist senktide was inactive, while the NK1 selective agonists septide and [Sar9Met(O2)11]SP displayed some effects. These results indicate that NK2 and also some NK1 receptors are present in monocytes isolated from healthy donors. The role of tachykinin receptor activation in rheumatoid arthritis was also investigated, by measuring O2- production and TNF-alpha mRNA expression in monocytes isolated from rheumatoid patients. Tachykinins enhanced the expression of this cytokine in both control and rheumatoid monocytes and NK2 receptor stimulation was shown to trigger an enhanced respiratory burst in monocytes from rheumatoid patients. In conclusion, these results indicate that NK2 and NK1 receptors are present on human monocytes, the former being preferentially involved in rheumatoid arthritis.